Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders

Podobne knjige/članki

• Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
  od: Alexandre Theocharides, et al.
  Izdano: (2007)
• Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
  od: Róbert Královics, et al.
  Izdano: (2005)
• A Gain-of-Function Mutation of<i>JAK2</i>in Myeloproliferative Disorders
  od: Róbert Královics, et al.
  Izdano: (2005)
• Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
  od: Daniela Pietra, et al.
  Izdano: (2007)
• Angiogenesis and vascular endothelial growth factor‐/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and <i>JAK2‐V617F</i> mutational status
  od: Michael Medinger, et al.
  Izdano: (2009)